Guardant Health Q4 revenue up 30% to $201.8M; 2025 revenue guidance $850-860M, convertible debt exchanged

Guardant Health, Inc.

2024-FY EPS reported -$3.56 revenue$739,016,000

Full-year 2024 revenue $739M (+31% YoY); net loss $436.4M ($3.56 loss per share); non-GAAP net loss $247.2M ($2.01 loss per share).
Q4 2024 revenue $201.8M (+30% YoY); net loss $111M ($0.90 loss per share); non-GAAP net loss $77.3M ($0.62 loss per share).
Completed convertible debt exchange: issued $600M 1.25% 2031 notes, retiring $659.3M of 0% 2027 notes; also repurchased $45M of common stock.
2025 guidance: revenue $850-860M (15-16% growth); oncology clinical volume growth expected to accelerate to ~25%; screening revenue $25-30M on 45-50K Shield tests.
Free cash flow burn improved to $275M in 2024; expects $225-235M in 2025; Guardant Reveal received Medicare coverage for CRC surveillance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.